Ziresovir

Names

[ Name ]:
Ziresovir

[Synonym ]:
4-Quinazolinamine, N-[(3-amino-3-oxetanyl)methyl]-2-(2,3-dihydro-1,1-dioxido-1,4-benzothiazepin-4(5H)-yl)-6-methyl-
N-[(3-Amino-3-oxetanyl)methyl]-2-(1,1-dioxido-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)-6-methyl-4-quinazolinamine

Biological Activity

[Description]:

Ziresovir (AK0529;RO-0529) is a potent, selective, and orally bioavailable respiratory syncytial virus (RSV) fusion (F) protein (RSV F) protein inhibitor. Ziresovir shows anti-RSV activity (EC50=3 nM) and highlights pharmacokinetics in animal species[1].

[Related Catalog]:

Research Areas >> Infection

Signaling Pathways >> Anti-infection >> RSV

[Target]

EC50: 3 nM (RSV F)[1]

[References]

[1]. Scott SA, et al. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol. 2009 Feb;5(2):108-17.

Chemical & Physical Properties

[ Density]:
1.4±0.1 g/cm3

[ Boiling Point ]:
745.4±70.0 °C at 760 mmHg

[ Molecular Formula ]:
C₂₂H₂₅N₅O₃S

[ Molecular Weight ]:
439.531

[ Flash Point ]:
404.6±35.7 °C

[ Exact Mass ]:
439.167816

[ LogP ]:
0.26

[ Vapour Pressure ]:
0.0±2.5 mmHg at 25°C

[ Index of Refraction ]:
1.679